Open AccessGemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531
Author(s) -
Jessica A. Pollard,
Erin Guest,
Todd A. Alonzo,
Robert B. Gerbing,
Mike R Loken,
Lisa Eidenschink Brodersen,
E. Anders Kolb,
Richard Aplenc,
Soheil Meshinchi,
Susana C. Raimondi,
Betsy Hirsch,
Alan S. Gamis
Publication year - 2021
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.20.03048
Subject(s) - medicine , gemtuzumab ozogamicin , oncology , chemotherapy , hematopoietic stem cell transplantation , etoposide , cd33 , disease , stem cell , cd34 , genetics , biology
We investigated the impact of the CD33-targeted agent gemtuzumab ozogamicin (GO) on survival in pediatric patients with KMT2A -rearranged ( KMT2A -r) acute myeloid leukemia (AML) enrolled in the Children's Oncology Group trial AAML0531 (NCT01407757).